

Velocity™ RapidSphere™ image-guided Y90 dosimetry*

Clinical Value

Kappadath SC, Mikell J, Balagopal A, Baladandayuthapani V, Kaseb A, Mahvash A. Hepatocellular Carcinoma Tumor Dose Response After 90Y-radioembolization With Glass Microspheres Using 90Y-SPECT/CT-Based Voxel Dosimetry. *Int J Radiat Oncol Biol Phys.* 2018 Oct 1;102(2):451-461. University of Texas MD Anderson Cancer Center, Houston, TX

Potrebko PS, Shridhar R, Biagioli MC, Sensakovic WF, Andl G, Poleszczuk J, Fox TH. SPECT/CT image-based dosimetry for Yttrium-90 radionuclide therapy: Application to treatment response. *J Appl Clin Med Phys.* 2018 Sep;19(5):435-443. University of Central Florida, Orlando, FL

Botta F, Ferrari M, Chiesa C, Vitali S, Guerriero F, Nile MC, Mira M, Lorenzon L, Pacilio M, Cremonesi M. Impact of missing attenuation and scatter corrections on 99m Tc-MAA SPECT 3D dosimetry for liver radioembolization using the patient relative calibration methodology: A retrospective investigation on clinical images. *Med Phys.* 2018 Apr;45(4):1684-1698. Istituto Europeo di Oncologia, Milan, Italy

Garin E, Rolland Y, Pracht M, Le Sourd S, Laffont S, Mesbah H, Haumont LA, Lenoir L, Rohou T, Brun V, Edeline J. High impact of macroaggregated albumin-based tumour dose on response and overall survival in hepatocellular carcinoma patients treated with 90 Y-loaded glass microsphere radioembolization. *Liver Int.* 2017 Jan;37(1):101-110. Cancer Institute Eugène Marquis, Rennes, France

Willowson KP, Tapner M; QUEST Investigator Team, Bailey DL. A multicentre comparison of quantitative (90)Y PET/CT for dosimetric purposes after radioembolization with resin microspheres: The QUEST Phantom Study. *Eur J Nucl Med Mol Imaging.* 2015 Jul;42(8):1202-22 University of Sydney, Sydney, Australia

Kao YH, Steinberg JD, Tay YS, Lim GK, Yan J, Townsend DW, Budgeon CA, Boucek JA, Francis RJ, Cheo TS, Burgmans MC, Irani FG, Lo RH, Tay KH, Tan BS, Chow PKh, Satchithanantham S, Tan AE, Ng DC, Goh AS. Post-radioembolization yttrium-90 PET/CT - part 2: dose-response and tumor predictive dosimetry for resin microspheres. *EJNMMI Res.* 2013 Jul 25;3(1):57. Singapore General Hospital, Singapore

Dezarn WA, Cessna JT, DeWerd LA, Feng W, Gates VL, Halama J, Kennedy AS, Nag S, Sarfaraz M, Sehgal V, Selwyn R, Stabin MG, Thomadsen BR, Williams LE, Salem R; American Association of Physicists in Medicine. Recommendations of the American Association of Physicists in Medicine on dosimetry, imaging, and quality assurance procedures for 90Y microsphere brachytherapy in the treatment of hepatic malignancies. *Med Phys.* 2011 Aug;38(8):4824-45. Medical Radiation Physics Inc., Milford, OH

Local Deposition Model

Mikell JK, Mahvash A, Siman W, Mourtada F, Kappadath SC. Comparing voxel-based absorbed dosimetry methods in tumors, liver, lung, and at the liver-lung interface for (90)Y microsphere selective internal radiation therapy. *EJNMMI Phys.* 2015 Dec;2(1):16. The University of Texas MD Anderson Cancer Center, Houston, TX

Pasciak AS, Bourgeois AC, Bradley YC. A Comparison of Techniques for (90)Y PET/CT Image-Based Dosimetry Following Radioembolization with Resin Microspheres. *Front Oncol.* 2014 May 22;4:121. The University of Tennessee Medical Center, Knoxville, TN

Gulec SA, Mesoloras G, Stabin M. Dosimetric techniques in 90Y-microsphere therapy of liver cancer: The MIRD equations for dose calculations. *J Nucl Med.* 2006 Jul;47(7):1209-11. Center for Cancer Care at Goshen Health System, Goshen, IN

* This bibliography is a representative selection, but not necessarily exhaustive list, of literature pertaining to Varian's Velocity RapidSphere image-guided Y90 dosimetry.

SPECT Calibration

Yue J, Mauxion T, Reyes DK, Lodge MA, Hobbs RF, Rong X, Dong Y, Herman JM, Wahl RL, Geschwind JH, Frey EC. Comparison of quantitative Y-90 SPECT and non-time-of-flight PET imaging in post-therapy radioembolization of liver cancer. *Med Phys.* 2016 Oct;43(10):5779. Johns Hopkins University, Baltimore, MD

Siman W, Mikell JK, Kappadath SC. Practical reconstruction protocol for quantitative (90)Y bremsstrahlung SPECT/CT. *Med Phys.* 2016 Sep;43(9):5093. The University of Texas MD Anderson Cancer Center, Houston, TX

Rong X, Du Y, Ljungberg M, Rault E, Vandenberghe S, Frey EC. Development and evaluation of an improved quantitative (90)Y bremsstrahlung SPECT method. *Med Phys.* 2012 May;39(5):2346-58. Johns Hopkins University, Baltimore, MD

Pasciak AS, Erwin WD. Effect of voxel size and computation method on Tc-99m MAA SPECT/CT-based dose estimation for Y-90 microsphere therapy. *IEEE Trans Med Imaging.* 2009 Nov;28(11):1754-8. The University of Texas MD Anderson Cancer Center, Houston, TX

Intended Use Summary

Varian Medical Systems' linear accelerators are intended to provide stereotactic radiosurgery and precision radiotherapy for lesions, tumors, and conditions anywhere in the body where radiation treatment is indicated.

Safety Statement

Radiation treatments may cause side effects that can vary depending on the part of the body being treated. The most frequent ones are typically temporary and may include, but are not limited to, irritation to the respiratory, digestive, urinary or reproductive systems, fatigue, nausea, skin irritation, and hair loss. In some patients, they can be severe. Treatment sessions may vary in complexity and time. Radiation treatment is not appropriate for all cancers.

varian

varian.com

USA, Corporate Headquarters and Manufacturer

Varian Medical Systems, Inc.
3100 Hansen Way
Palo Alto, CA 94304
Tel: 650.424.5700
800.544.4636

Headquarters Europe, Eastern Europe, Middle & Near East, India, Africa

Varian Medical Systems International AG
Steinhausen, Switzerland
Tel: 41.41.749.8844

Asia Pacific Headquarters

Varian Medical Systems Pacific, Inc.
Kowloon, Hong Kong
Tel: 852.2724.2836

Australasian Headquarters

Varian Medical Systems Australasia Pty Ltd.
Sydney, Australia
Tel: 61.2.9485.0111

Latin American Headquarter

Varian Medical Systems Brasil Ltda.
São Paulo, Brazil
Tel: 55.11.3457.2655